• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)
临床输血与检验

临床输血与检验 ›› 2017, Vol. 19 ›› Issue (5): 478-481.DOI: 10.3969/j.issn.1671-2587.2017.05.021

• 临床检验 • 上一篇    下一篇

肝细胞肝癌患者血清PF4、VEGF、HIF-1α及Lp（a）的表达及临床意义*

唐永华, 许海涛, 刘小君, 刘良田, 李阳华   

  1. 518106 广东省深圳市光明新区人民医院（唐永华,许海涛,刘小君,李阳华）; 宝安区石岩人民医院输血科（刘良田）
  • 收稿日期:2017-06-02 出版日期:2017-10-20 发布日期:2017-10-26
  • 作者简介:唐永华（1977-）,男,主管技师,学士,主要从事临检及生化免疫工作,（Tel）18126081835（E-mail）tangyonghua1977@163.com。
  • 基金资助:
    *本课题受广东省深圳市宝安区科技创新项目（No.2016CX106）资助

Clinical Significance of PF4,VEGF,HIF-1a and Lpα in Sera of Patients with Hepatocellular Carcinoma

TANG Yong-hua, XU Hai-tao, LIU Xiao-jun et al   

  1. Clinical Laboratory and Department of Internal Medicine of Shenzhen Guangming New District Hospital,Guangdong province,Shenzhen 518108
  • Received:2017-06-02 Online:2017-10-20 Published:2017-10-26

PDF

706

摘要： 目的 探讨血小板第4因子（PF4）、血管内皮生长因子（VEGF）、乏氧诱导因子-1α（HIF-1α）及脂蛋白（a）[Lp（a）]在肝细胞肝癌（hepatocellular carcinoma,HCC）患者血清中的表达及其临床意义。方法 收集2014年3月~2016年12月年本院确诊的慢性乙型肝炎（chronic hepatitis B,CHB）102例、肝硬化（1iver cirrhosis,LC）51例、HCC患者37例及健康对照组（health control,HC）186例,采用免疫增强比浊法测定受试者血清中Lp（a）浓度,同时采用酶联免疫吸附试验（ELISA）测定血清PF4、HIF-la和VEGF含量,并对检测结果进行统计分析。结果 PF4、VEGF、HIF-1α和Lp（a）浓度在HCC组明显高于CHB、LC和HC组,差异均有统计学意义（t=6.185~15.916,P<0.001~0.05）,且III期HCC明显高于I期和II期,差异均有统计学意义（t=7.951~19.086,P<0.001~0.05）,CHB、LC和HC组血清PF4、VEGF及HIF-1α浓度的差异无统计学意义（t=0.371~0.892,P>0.05）;LC组Lp（a）浓度明显低于其他组,差异均有统计学意义（t=6.176~9.452,P<0.05）,且III级LC明显低于I级和II级,差异均有统计学意义（t=4.945~6.067,P<0.05）。结论 PF4、VEGF、HIF-1α和Lp（a）浓度在HCC血清中明显增高,且随临床分期/级越大,浓度增幅越高,可作为临床HCC诊断及分期依据;Lp（a）浓度LC组明显降低,可作为LC诊断及与HCC鉴别诊断依据。

关键词: 血小板第4因子, 血管内皮生长因子, 乏氧诱导因子-1α, 脂蛋白a, 肝细胞肝癌

Abstract: Objective To investigate the levels and clinical significance of platelet factor 4 （PF4）,vascular endothelial growth factor（VEGF）,hypoxia inducible factor-1α（HIF-1α） and lipoprotein α（Lp α） in hepatocellular carcinoma （HCC）. Method The investigation included 102 inpatients of chronic hepatitis B（HCB）,51 of liver cirrhosis,37 of HCC,and 186 subjects of healthy controls（HC） between 2014 and 2016. All samples were detected with immune enhanced turbidimetric method for serum concentration of Lpα and with ELISA for seral PF4,HIF - la and VEGF. Results The PF4,VEGF,HIF-1a and Lpα concentrations in HCC patients were obviously higher than those of CHB and LC patients,and HC as well （P<0.001~0.05）,showing a stage-dependent increase of the markers tested（t=7.951-19.086,P<0.001-0.05）. No remarkable variation was noted of PF4,VEGF,and HIF-1α in the three groups（P>0.05）. Lpαlevel,however,was found to be higher in LC group than in the other groups（P<0.05）,reversely showing a stage-dependent decrease（P<0.05）. Conclusion sPF4,VEGF,HIF-1α and Lpαlevels are significantly elevated in the sera of HCC patients,based on which a differential diagnosis between LC and HCC can be made.

Key words: Platelet factor-4, Vascular endothelial growth factor, Hypoxia inducible factor-1α, Lipoprotein（a）, Hepatocellular carcinoma

中图分类号: